VAXART (VXRT)
(Delayed Data from NSDQ)
$0.84 USD
0.00 (0.26%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $0.84 0.00 (0.41%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Brokerage Reports
0 items in cart
VAXART, INC. [VXRT]
Reports for Purchase
Showing records 1 - 15 ( 15 total )
Company: VAXART, INC.
Industry: Medical - Drugs
Company: VAXART, INC.
Industry: Medical - Drugs
Company: VAXART, INC.
Industry: Medical - Drugs
Oral COVID-19 Vaccine Momentum Continues With Completion of Phase 1 Enrollment; Reiterate Buy and $17 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: VAXART, INC.
Industry: Medical - Drugs
One Step Closer to Joining the Coronavirus Vaccine Race; Reiterate Buy and $17 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: VAXART, INC.
Industry: Medical - Drugs
2Q20 and Early 3Q20 Activities Position Oral COVID-19 Vaccine Value to Emerge.
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: VAXART, INC.
Industry: Medical - Drugs
Pivoting to Develop a CoV Vaccine but This One?s Very Different; Reiterate Buy and $7 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: VAXART, INC.
Industry: Medical - Drugs
Corporate Update Shows Strong Progress in the COVID-19 Program; Raising PT to $7
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: VAXART, INC.
Industry: Medical - Drugs
Positive Preclinical Progress Demonstrated in Oral COVID-19 Vaccine Development Program; Reit Buy Rating and $3 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: VAXART, INC.
Industry: Medical - Drugs
Corporate Update Highlighted by a Call of Duty in the Fight Against COVID-19; Reiterate Buy and $3 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: VAXART, INC.
Industry: Medical - Drugs
Agreement With EBS Provides Future Vaccine Manufacturing Scalability; Reiterate Buy and $3 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: VAXART, INC.
Industry: Medical - Drugs
Tracking the Course of the Coronavirus Epidemic: KOL Conference Call Recap
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: VAXART, INC.
Industry: Medical - Drugs
An Oral Coronavirus Vaccine Could Become a Significant Long- Term Value-Creation Opportunity.
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: VAXART, INC.
Industry: Medical - Drugs
KOL Analysis Suggests Potential Upside in Our Norovirus Model; Reiterate Buy and $2 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: VAXART, INC.
Industry: Medical - Drugs
Norovirus Phase 1b Data Could Be a Major 4Q19 Catalyst; Reiterate Buy and $2 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: VAXART, INC.
Industry: Medical - Drugs
|